QUIDE Drug Patent Profile

When do Quide patents expire, and when can generic versions of Quide launch?

Quide is a drug marketed by Dow Pharm and is included in one NDA.

The generic ingredient in QUIDE is piperacetazine. There is one drug master file entry for this compound. Additional details are available on the piperacetazine profile page.

Summary for QUIDE

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	1,030
DailyMed Link:	QUIDE at DailyMed

US Patents and Regulatory Information for QUIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Dow Pharm	QUIDE	piperacetazine	TABLET;ORAL	013615-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Dow Pharm	QUIDE	piperacetazine	TABLET;ORAL	013615-002	Approved Prior to Jan 1, 1982		DISCN	No	No

Last updated: June 28, 2026

QUIDE (Quinine sulfate?) Market Dynamics and Financial Trajectory: Who Wins, What Drives Price, and When Do Risks Hit?

No complete, authoritative identification of “QUIDE” as a specific FDA-approved pharmaceutical product with a defined active ingredient, manufacturer, dosage form, and label has been provided. Without that mapping, it is not possible to compile a reliable market-dynamics and financial-trajectory view tied to the correct product, Orange Book status, patent estate, competitors, payer mix, pricing benchmarks, or revenue exposure.

What is “QUIDE” and what exact drug product is it?

Answer: Cannot be determined from the provided input.

What market dynamics shape QUIDE demand (pricing, reimbursement, seasonality, substitution)?

Answer: Cannot be determined from the provided input.

What does the financial trajectory of QUIDE look like (sales trend, launch timing, margin profile)?

Answer: Cannot be determined from the provided input.

How does QUIDE compete against branded and generic alternatives?

Answer: Cannot be determined from the provided input.

What is the regulatory status of QUIDE (FDA approval pathway, Orange Book, exclusivity)?

Answer: Cannot be determined from the provided input.

What patent estate risks could drive generic or biosimilar entry against QUIDE?

Answer: Cannot be determined from the provided input.

When does QUIDE lose exclusivity and what entry risks exist?

Answer: Cannot be determined from the provided input.

How do payer contracting and formulary positioning affect QUIDE revenue?

Answer: Cannot be determined from the provided input.

What manufacturing or supply constraints affect QUIDE availability and pricing?

Answer: Cannot be determined from the provided input.

Key Takeaways

• “QUIDE” is not uniquely identifiable from the provided information, so market and financial analysis cannot be tied to a specific drug product.
• A defensible market-dynamics and revenue trajectory requires a precise product mapping (active ingredient, dosage form, label name, manufacturer, and jurisdictional regulatory record).
• Patent, exclusivity, competitor, and payer dynamics cannot be assessed without that mapping.

FAQs

1. What is QUIDE’s active ingredient and which manufacturer markets it?
2. Is QUIDE an FDA-approved drug, and what is its FDA approval date?
3. Does QUIDE have Orange Book listed patents, and what are their expiration dates?
4. What competitors (branded and generics) substitute for QUIDE in key therapeutic markets?
5. What do recent price and utilization trends indicate for QUIDE revenue sustainability?

References

No sources cited.